Clinical Trials Logo

Clinical Trial Summary

This study is to investigate the safety, tolerability and immunogenicity of the typhoid fever vaccine candidate M01ZH09 manufactured at commercial scale, at a new manufacturing facility. The vaccine will be delivered as a single oral dose to healthy, typhoid vaccine-naïve adults.


Clinical Trial Description

This was a randomised, double-blind, placebo-controlled, single dose, dose escalation study with 4 dosing cohorts. Within each cohort, 45 evaluable subjects were planned (36 subjects receiving M01ZH09, 9 receiving placebo). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00679172
Study type Interventional
Source Emergent BioSolutions
Contact
Status Completed
Phase Phase 2
Start date May 2008
Completion date December 2008

See also
  Status Clinical Trial Phase
Completed NCT03312699 - Effects of Aging on Primary and Secondary Vaccine Responses in a 15-Year Longitudinal Cohort Phase 1
Completed NCT01405521 - Understanding Typhoid Disease After Vaccination Phase 2
Completed NCT00125047 - Combined Vi Vaccination and Health Education Program on the Burden of Typhoid in Childhood Phase 4
Completed NCT00131833 - Typhoid Vi Vaccine Effectiveness in Hechi, Guangxi, China Phase 4
Not yet recruiting NCT05771779 - Co-administration Study of OCV, TCV and MR Phase 3
Completed NCT01466387 - A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults Phase 3
Active, not recruiting NCT03933098 - Immune Non-inferiority and Safety of a Vi-DT Typhoid Conjugate Vaccine Phase 3
Completed NCT00125008 - Evaluation of the Vi Polysaccharide Vaccine Against Typhoid Fever Phase 4
Recruiting NCT04878549 - Transcriptomic Responses for the Identification of Pathogens
Completed NCT02645032 - Safety and Immunogenicity of a Vi-DT Typhoid Conjugate Vaccine Phase 1
Recruiting NCT05475379 - Non-inferiority Trial of Locally Manufactured Typhoid Conjugate Vaccine 'Typhocon' in Bangladesh Phase 1/Phase 2
Completed NCT04204096 - Immune Equivalence Between Multi-dose and Single Dose Formulation of Vi-DT and Their Overall Safety (Phase III) Phase 3
Active, not recruiting NCT03299426 - Clinical Efficacy of Typhoid Conjugate Vaccine (Vi-TCV) Among Children Age 9 Months Through 12 Years in Blantyre, Malawi Phase 3
Completed NCT01019083 - Studies of Immune Responses to Orally Administered Vaccines in Developing Country Phase 1/Phase 2
Completed NCT03614533 - Typhoid Conjugate Vaccine Trial Among Children Younger Than 2 Years in Ouagadougou, Burkina Faso Phase 2
Completed NCT00131820 - Introduction of the Vi Polysaccharide Typhoid Vaccine in Hue City, Central Vietnam Phase 4
Completed NCT03527355 - Safety, Reactogenicity and Immunogenicity of Vi-DT;Typhoid Conjugate Vaccine Phase 2